Cyclerion Therapeutics, Inc.
CYCN
$26.20
$2.6811.40%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | 1.03M | 875.00K | 93.00K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | 1.03M | 875.00K | 93.00K |
| Cost of Revenue | -- | 730.00K | 519.00K | 348.00K | 56.00K |
| Gross Profit | -- | -730.00K | 506.00K | 527.00K | 37.00K |
| SG&A Expenses | 1.77M | 2.48M | 1.34M | 1.53M | 1.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 1.77M | 3.21M | 1.86M | 1.88M | 1.77M |
| Operating Income | -1.77M | -3.21M | -838.00K | -1.01M | -1.67M |
| Income Before Tax | -1.76M | -3.18M | -799.00K | -976.00K | -324.00K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -1.76M | -3.18M | -799.00K | -976.00K | -324.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.76M | -3.18M | -799.00K | -976.00K | -324.00K |
| EBIT | -1.77M | -3.21M | -838.00K | -1.01M | -1.67M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -2.89 | -5.29 | -1.47 | -2.12 | -0.74 |
| Normalized Basic EPS | -1.81 | -3.31 | -0.92 | -1.32 | -2.34 |
| EPS Diluted | -2.89 | -5.29 | -1.47 | -2.12 | -0.74 |
| Normalized Diluted EPS | -1.81 | -3.31 | -0.92 | -1.32 | -2.34 |
| Average Basic Shares Outstanding | 607.30K | 600.70K | 544.40K | 460.70K | 438.70K |
| Average Diluted Shares Outstanding | 607.30K | 600.70K | 544.40K | 460.70K | 438.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |